GSE77013

A long noncoding RNA signature in Ulcerative Colitis

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

12 case / 0 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Background & Aims: Inflammatory bowel diseases (IBD) are clinically manifested as ulcerative colitis (UC) and Crohn’s Disease (CD). Novel high throughput technologies revealed new categories of genes, including the long non-coding RNAs (lncRNAs), which have been involved in the pathogenesis of different human diseases; however the role and function of lncRNAs in the UC pathogenesis has not been evaluated. Methods: The gene expression patterns for both non-coding (lncRNAs) and coding (mRNA) transcripts were profiled in UC (n=8) and control (n=7) patients by ArrayStar assays. The differentially expressed genes were used to develop lncRNA signatures in UC samples. Ingenuity Software Analysis (IPA) program was used to identify the up-stream regulators of IFNG-AS1. Jurkat T cells were activated by PMA/ionomycin and IFNG and TNF protein levels were assessed by ELISA assay. Two anti-sense molecules were designed and used to block IFNG-AS1 expression levels. Colonic tissues from TNBS-treated and IL10-/- mice were used to extract RNA and examine INFG-AS1 expression by real-time PCR. Results: A unique set of lncRNAs was found to be differentially expressed between UC (n=15) and control samples (n=16). Of these, IFNG-AS1 was among the highest statistically significant lncRNAs (fold change: 5.27, p-value: 7.07E-06). Bioinformatic analyses showed that IFNG-AS1 was associated with the IBD susceptibility loci SNP rs7134599 and its genomic location is adjacent to the inflammatory cytokine, interferon-gamma (IFNG). Using the TNBS and IL10-/- mouse models of colitis, we found increased colonic expression of this lncRNA during active colitis. Utilizing the Jurkat T cell model system, we explored the mechanisms of action and found that IFNG-AS1 can positively regulate IFNG expression. Conclusions:   Novel lncRNA signatures were identified to differentiate UC patients with active disease, in remission and control subjects. A subset of these lncRNAs was found to be associated with the clinically validated IBD susceptibility loci.  IFNG-AS1 was one of these differentially expressed lncRNAs in UC patients and was found to regulate the key inflammatory cytokine, IFNG, in CD4 T cells.  Taken together, our study revealed novel lncRNA signatures deregulated in ulcerative colitis and identified IFNG-AS1 as a novel regulator of IFNG inflammatory responses, suggesting the potential importance of non-coding RNA mechanisms on regulation of IBD-related inflammatory responses.

Overall design

19 overall samples were analyzed. Colonic resection samples from 8 Active Ulcerative colitis, 4 Inactive Ulcerative colitis, 7 control samples

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
19 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation. American journal of physiology. Gastrointestinal and liver physiology, 2016
Available

Metadata Quality Components

Analysis Readiness

Not ready
43% DE readiness

Contrast completeness

10/25 pts

Only one side of the contrast is present; downstream DE needs both groups.

Minimum group size

0/20 pts

Minimum group size cannot be evaluated until a complete contrast exists.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

3/15 pts

Unassigned or review-needed samples remain before analysis.

Blocking warnings

0/10 pts

Critical warnings must be resolved before downstream analysis.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • No complete case/control contrast is available.
  • 7 samples are still unassigned.
  • Critical dataset warnings must be resolved.
  • Secondary RNA assay context should be analyzed separately from ordinary bulk RNA-seq.

Next Steps

  • Resolve unassigned or review-needed samples in the grouping table.
  • Resolve critical warnings before downstream analysis.

Analysis Preparation Checklist

3/6 ready

Group labels reviewed

Blocked

No complete case/control grouping exists yet.

Review the sample grouping table and assign both case and control groups.

Minimum sample count met

Blocked

At least one group has fewer than 2 samples.

Choose a larger dataset or merge only scientifically valid groups.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Needs review

0 review-needed samples and 7 unassigned samples remain.

Resolve ambiguous and unassigned samples before finalizing the contrast.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Analysis preparation checklist contains blocked items.

No complete case/control or treatment/control contrast is available.

At least one comparison group has fewer than two samples.

One or more samples are unassigned and need manual grouping decisions.

Critical dataset warnings are present.

Assay context may require expert handling before DESeq2-style analysis.

Study design is model-system or unclear and should be reviewed before analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Crohn's disease, inflammatory bowel disease, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Ulcerative colitis 12 samples
  • Likely control group No control group detected 0 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Unclear study design. Specimen: Tissue. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Interpreted disease metadata: Crohn's disease, Inflammatory bowel disease, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 27492330.
  • Publication context: A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation.. American journal of physiology. Gastrointestinal and liver physiology, 2016. PMID 27492330. DOI 10.1152/ajpgi.00212.2016.

Cautions

  • Comparison: Unclear study design. Specimen: Tissue. Comparison suitability: 0%.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Missing or unclear metadata. Comparison - Unclear study design. Specimen - Tissue. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

57 fields

Sample Group Preview

19 rows shown
Show Hide
Study totals: Case 12 | Control 0 | Unassigned 7 | Excluded 0 | Ambiguous 0 19 rows shown
Group Role Accession Title Source / characteristics Reason
Ulcerative colitis Case GSM2042471 UCA1 Colon tissue Age: 30; Gender: Female; Location: Colon; Sample type: Active ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042472 UCA2 Colon tissue Age: 56; Gender: Female; Location: Colon:Left; Sample type: Active ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042473 UCA3 Colon tissue Age: 26; Gender: Female; Location: Colon; Sample type: Active ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042474 UCA4 Colon tissue Age: 46; Gender: Female; Location: Colon; Sample type: Active ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042475 UCA5 Colon tissue Age: 29; Gender: Male; Location: Colon; Sample type: Active ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042476 UCA6 Colon tissue Age: 24; Gender: Male; Location: Colon; Sample type: Active ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042477 UCA7 Colon tissue Age: 45; Gender: Female; Location: Colon; Sample type: Active ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042478 UCA8 Colon tissue Age: 26; Gender: Female; Location: Colon; Sample type: Active ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042479 UCI1 Colon tissue Age: 31; Gender: Male; Location: Colon; Sample type: Inactive ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042480 UCI2 Colon tissue Age: 71; Gender: Female; Location: Colon; Sample type: Inactive ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042481 UCI3 Colon tissue Age: 51; Gender: Male; Location: Colon; Sample type: Inactive ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM2042482 UCI4 Colon tissue Age: 33; Gender: Female; Location: Colon; Sample type: Inactive ulcerative colitis Case marker detected.
Unassigned Unassigned GSM2042464 Con1 Colon tissue Age: 31; Gender: Male; Location: Colon; Sample type: Control No explicit case or control marker detected.
Unassigned Unassigned GSM2042465 Con2 Colon tissue Age: 45; Gender: Female; Location: Colon; Sample type: Control No explicit case or control marker detected.
Unassigned Unassigned GSM2042466 Con3 Colon tissue Age: 26; Gender: Male; Location: Colon:Sigmoid; Sample type: Control No explicit case or control marker detected.
Unassigned Unassigned GSM2042467 Con4 Colon tissue Age: 46; Gender: Male; Location: Colon; Sample type: Control No explicit case or control marker detected.
Unassigned Unassigned GSM2042468 Con5 Colon tissue Age: 50; Gender: Female; Location: Colon; Sample type: Control No explicit case or control marker detected.
Unassigned Unassigned GSM2042469 Con6 Colon tissue Age: 60; Gender: Female; Location: Colon; Sample type: Control No explicit case or control marker detected.
Unassigned Unassigned GSM2042470 Con7 Colon tissue Age: 56; Gender: Male; Location: Colon; Sample type: Control No explicit case or control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.